ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases

The increasing incidence of breast cancer brain metastases is a major clinical problem with its associated poor prognosis and limited treatment options. The long-acting topoisomerase-1 inhibitor, etirinotecan pegol, was designed to preferentially accumulate in tumor tissue including brain metastases...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Future Oncol
Autori principali: Tripathy, Debu, Tolaney, Sara M, Seidman, Andrew D, Anders, Carey K, Ibrahim, Nuhad, Rugo, Hope S, Twelves, Chris, Dieras, Veronique, Müller, Volkmar, Tagliaferri, Mary, Hannah, Alison L, Cortés, Javier
Natura: Artigo
Lingua:Inglês
Pubblicazione: Future Medicine Ltd 2019
Soggetti:
Clinical Trial Protocol
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7466911/
https://ncbi.nlm.nih.gov/pubmed/31074641
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon-2019-0180
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi